FAF2

FAF2/UBXD8 is a membrane-embedded, multi-domain adaptor protein that recruits the AAA-ATPase p97/VCP to the ER, lipid droplets, mitochondria, ER-mitochondria contact sites, and peroxisomes, coupling ubiquitin-dependent substrate extraction to proteasomal degradation across multiple organellar quality-control pathways. Its UBA, UAS, and UBX domains enable recognition of ubiquitinated substrates and p97 engagement: the UAS domain directly senses long-chain unsaturated fatty acids, which induce its oligomerization and relieve FAF2-mediated inhibition of triglyceride synthesis, while a helix-UBX segment positions the Ufd1 cofactor on p97 to stimulate substrate unfolding and degradation (PMID:21115839, PMID:23720822, PMID:41790892). FAF2 mediates sterol-induced HMGCR dislocation, lipidated ApoB-100 turnover on lipid droplets, degradation of pro-apoptotic BH3-only proteins at mitochondria, control of ER-mitochondria contact site extent via SREBP1/SCD1, suppression of pexophagy through regulation of peroxisomal membrane protein ubiquitination, and HuR release from mRNPs leading to mRNA destabilization (PMID:28882874, PMID:22238364, PMID:35979733, PMID:36746962, PMID:39929145, PMID:23618873). On lipid droplets, FAF2 additionally inhibits ATGL-mediated lipolysis by directly binding ATGL and dissociating its coactivator CGI-58, with its ER-to-LD trafficking regulated by the rhomboid pseudoprotease UBAC2 (PMID:23297223).

1. 2002 Low

   Initial identification of FAF2 (ETEA) as a Fas-associated protein established it as a potential component of death-receptor signaling, though its functional role remained unclear.

   Evidence Yeast two-hybrid screen identifying interaction with the Fas death domain; EGFP fusion localization

   PMID:12372427

   Open questions at the time

   • Interaction with Fas not validated by reciprocal co-IP or in vitro binding
   • No functional consequence of the Fas interaction demonstrated
   • Cytoplasmic localization does not resolve membrane association
2. 2009 High

   Demonstration that FAF2 dynamically shuttles between the ER and nascent lipid droplets via lateral membrane diffusion established its dual-organelle residency and linked it to lipid droplet biogenesis.

   Evidence Live-cell fluorescence imaging with EGFP-FAF2, dominant-negative Sar1, protein synthesis inhibition in mammalian cells

   PMID:19773358

   Open questions at the time

   • Membrane anchor topology not fully resolved
   • Signal triggering ER-to-LD migration not identified at the molecular level
3. 2010 High

   Two studies revealed FAF2's dual biochemical activities: direct sensing of unsaturated fatty acids via conformational change and oligomerization that controls triglyceride synthesis, and UBX-domain-dependent ubiquitination and degradation of neurofibromin, establishing FAF2 as both a lipid sensor and a p97-dependent degradation adaptor.

   Evidence In vitro reconstitution with purified recombinant FAF2 (thermal stability, limited proteolysis, native PAGE oligomerization) plus siRNA knockdown for lipid synthesis; proteomics-identified neurofibromin interaction, in vitro ubiquitination assay, domain mutants with Ras activity readout

   PMID:20160012 PMID:21115839

   Open questions at the time

   • Identity of the fatty acid binding site within the UAS domain not structurally resolved
   • Whether neurofibromin ubiquitination is a direct E3 activity or requires a recruited E3 ligase
4. 2012 High

   Showing that FAF2 recruits p97 to lipid droplets for post-dislocation degradation of lipidated ApoB-100 defined it as the critical LD-localized adaptor for ERAD-like substrate processing outside the ER.

   Evidence siRNA knockdown of UBXD8, co-IP with Derlin-1 and ApoB, immunofluorescence of p97 recruitment to LDs

   PMID:22238364

   Open questions at the time

   • Whether other UBX-domain proteins can substitute for FAF2 on LDs
   • Structural basis of FAF2-Derlin-1 interaction unknown
5. 2013 High

   Multiple 2013 studies expanded FAF2's mechanistic repertoire: (1) UBAC2 was identified as an ER-resident factor restricting FAF2 LD trafficking; (2) FAF2 was shown to inhibit ATGL lipolysis by direct binding and CGI-58 displacement on LDs; (3) the UAS domain's positively charged surface was mapped as the UFA-sensing oligomerization interface; (4) the p97-FAF2 complex was linked to mRNP remodeling via K29-ubiquitin-dependent HuR release.

   Evidence Co-IP and live-cell imaging for UBAC2 interaction; in vitro binding assay of purified FAF2 to ATGL; UAS domain mutagenesis with native PAGE; RNA immunoprecipitation and ubiquitin linkage analysis for HuR/mRNA regulation

   PMID:23297223 PMID:23618873 PMID:23720822

   Open questions at the time

   • Structural model of UAS-UFA complex lacking
   • Mechanism by which K29-linked ubiquitin on HuR is generated not identified
   • Whether UBAC2-mediated retention is regulated by metabolic cues
6. 2013 Medium

   The finding that ALS-linked UBQLN2 mutations impair interaction with FAF2 and compromise ERAD connected FAF2 to neurodegenerative disease pathology.

   Evidence Co-IP of UBQLN2 and FAF2 in vitro and in vivo; ERAD substrate accumulation with mutant UBQLN2

   PMID:24215460

   Open questions at the time

   • UBQLN2-FAF2 interaction not validated by independent lab
   • Whether FAF2 loss alone phenocopies UBQLN2-mutant ERAD defects not tested
   • Structural basis of the UBQLN2-FAF2 interaction unknown
7. 2017 High

   Identification of FAF2 as essential for sterol-induced HMGCR degradation via an unbiased haploid genetic screen established it as a non-redundant component of cholesterol homeostasis, with the UBX domain required for membrane dislocation.

   Evidence CRISPR/Cas9 haploid screen, UBXD8 KO and rescue, UBX domain deletion, HMGCR dislocation assay in multiple cell types

   PMID:28882874

   Open questions at the time

   • Whether FAF2 directly contacts HMGCR or acts via Insig/gp78 complex
   • In vivo cholesterol phenotype in FAF2 knockout animals not reported
8. 2022 High

   Discovery of FAF2 localization to mitochondria and its role in degrading pro-apoptotic BH3-only proteins (Noxa, Bik, Bnip3) revealed it as a mitochondrial quality-control factor restraining apoptosis and mitophagy.

   Evidence Subcellular fractionation, co-IP with mitochondrial E3 ligases, UBXD8 KO with apoptosis and mitophagy phenotype, substrate ID by mass spectrometry

   PMID:35979733

   Open questions at the time

   • How FAF2 is targeted to OMM versus ER versus LDs not resolved
   • Which mitochondrial E3 ligase is the primary partner
9. 2023 High

   Localization of the p97-FAF2 complex to ER-mitochondria contact sites and demonstration that its loss increases ERMCS extent and elevates membrane lipid saturation via SREBP1/SCD1 identified FAF2 as a regulator of inter-organelle contact site homeostasis and lipid composition.

   Evidence Proximity ligation, quantitative proteomics and lipidomics of ERMCS fractions, UBXD8 KO, p97 inhibitor, SREBP1/SCD1 epistasis

   PMID:36746962

   Open questions at the time

   • Specific ERMCS substrate(s) extracted by p97-FAF2 not identified
   • Whether ERMCS regulation is direct or secondary to lipid composition changes
10. 2025 Medium

    Two studies established FAF2 as a suppressor of pexophagy by controlling ubiquitination of peroxisomal membrane proteins (PMP70/ABCD3), with UBX and UAS domains required for peroxisome homeostasis and protection against saturated fatty acid stress.

    Evidence Quantitative proteomics, FAF2 KO, pexophagy flux assay, ABCD3 ubiquitination assay, USP30 rescue, genome-wide CRISPR screen, domain deletion analysis

    PMID:39929145 PMID:40601736

    Open questions at the time

    • Which E3 ligase ubiquitinates ABCD3 under FAF2 control not identified
    • Whether FAF2 localizes to peroxisomes directly or acts from ER
    • Independent replication of peroxisome phenotype by additional labs needed
11. 2025 High

    Engineering polyserine-targeted FAF2 to suppress tau aggregation in cell, fly, and mouse models demonstrated that FAF2's ubiquitin-dependent degradation machinery can be redirected to pathological protein aggregates, establishing therapeutic proof-of-concept.

    Evidence Polyserine targeting in tau aggregation assays, domain deletion mutants, Drosophila neurodegeneration model, PS19 mouse model with behavioral and biochemical readouts

    PMID:40902597

    Open questions at the time

    • Whether endogenous FAF2 engages tau in unmodified settings unknown
    • Long-term safety and off-target degradation not assessed
    • Mechanism by which membrane-localized FAF2 accesses cytoplasmic tau aggregates unclear
12. 2026 High

    In vitro reconstitution revealed that FAF2 stimulates p97-Ufd1-Npl4-mediated substrate unfolding and proteasomal degradation by positioning Ufd1's UT3 ubiquitin-binding module on the p97 N-domain via a helix-UBX segment, resolving the long-standing question of how UBX-domain cofactors enhance p97 processivity.

    Evidence In vitro reconstitution of p97-mediated unfolding coupled to proteasomal degradation with purified components; site-directed mutagenesis of helix-Ufd1 interface

    PMID:41790892

    Open questions at the time

    • Whether the helix-UBX mechanism is shared by FAF1 in vivo
    • Structural resolution of the ternary FAF2-Ufd1-p97 complex lacking
    • Contribution of UBA domain to substrate selection during unfolding not tested

• Major open questions include: the structural basis for UAS domain fatty acid sensing and oligomerization; how FAF2 is differentially targeted to ER, lipid droplets, mitochondria, ERMCS, and peroxisomes; and whether FAF2 loss in vivo causes metabolic or neurological disease in mammals.
• No high-resolution structure of full-length FAF2 or the UAS-UFA complex
• No animal knockout phenotype systematically characterized
• Mechanisms governing organelle-specific targeting of a single membrane-embedded adaptor unresolved